A single-center, open-label, single-dose study investigating the safety, tolerability, and pharmacokinetic properties of nalmefene 10 mg tablets in healthy Japanese male subjects

Trial Profile

A single-center, open-label, single-dose study investigating the safety, tolerability, and pharmacokinetic properties of nalmefene 10 mg tablets in healthy Japanese male subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Nalmefene (Primary)
  • Indications Alcoholism
  • Focus Pharmacokinetics
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 25 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 08 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.
    • 08 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top